Karolinska Development’s portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and D

Core Insights - Karolinska Development AB's portfolio company SVF Vaccines has presented promising preclinical data on its immunotherapy SVF-001, targeting hepatitis B and D, at the HepDart scientific meeting [1][3] - The new data indicates sustained antiviral activity of SVF-001, showing reductions in hepatitis D virus RNA in blood for up to six weeks post-treatment [2][4] - Karolinska Development holds a 33% ownership stake in SVF Vaccines, which also includes other vaccine candidates like SVF-002 for COVID-19 [5] Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations [6][7] - The company aims to build companies around leading scientists and experienced management teams, co-funded by international investors [7][8] - The portfolio includes eleven companies targeting innovative treatments for serious diseases, emphasizing a strong global network and proven track record in company building [8]